65,437 trials
Acute Coronary Syndrome
Primary: Time to First Occurence of Primary CV Event: CV Death, Non-Fatal MI, Non-Fatal Stroke or Hospitalization for Unstable Angina — 399; 406 participants — p=0.8542
Type 2 Diabetes Mellitus
Primary: Change in HbA1c From Baseline to Week 24 — -0.65; -0.74 Percentage of hemoglobin — p=0.2664
Type 2 Diabetes
Primary: Absolute Change in HbA1c From Baseline to Week 24 — -0.57; 0.06 percentage of hemoglobin — p=< 0.0001
Pressure Ulcer
Primary: Erythema ( No/Yes) — 5; 24; 16; 13 participants
Cardiovascular Disease · Childhood ALL · Childhood NHL
Primary: Change From Baseline in Brachial Artery Flow-Mediated Dilation at 6-months — -0.5; -3.4 percentage change
Venous Thromboembolism
Primary: Number of Participants With Postoperative VTE Within 48 Hours After Surgery — 5; 3 participants — p=0.72
Insomnia
Primary: Number of Participants Reporting One or More Adverse Drug Reactions — 0 participants
Ischemic Stroke · Obstructive Sleep Apnea
Primary: Apnea-hypopnea Index — 17.1; 25.2 apneas plus hypopneas per hour — p=0.183
Hepatitis C · Liver Disease
Primary: Change From Baseline in Hepatitis C Virus Ribonucleic Acid Viral Load at Week 12 — 6.323; 6.343; -3.935; -3.855 log10 IU/mL
Smoking
Primary: Concentration of Monohydroxybutenyl Mercapturic Acid (MHBMA) — 194.05; 2314.37; 168.01 pg/mg creat — p=<0.001
Nicotine Dependence
Primary: Quit Rate — 18; 15 participants
Pain
Primary: Pain Levels — 4.8; 4.0; 4.7; 4.0 units on a scale — p=<0.05
Leukemia, Myeloid, Acute · Myelodysplastic Syndromes
Primary: Phase I: Maximum Tolerated Dose (MTD) of LBH589 When Given in Combination With Decitabine — 40 mg (level 5b dosing schedule)
Lymphoma, B-Cell · Lymphoma, Large B-Cell, Diffuse · Lymphoma, Non-Hodgkin
Primary: Objective Response Rate (ORR) by Investigator With Brentuximab Vedotin Monotherapy — 41; 26; 44; 31 percentage of participants
Cervical Carcinoma
Primary: Number of Women Who Receive a Pap Smear Test — 209; 30 participants — p=<0.001